Giannini Edoardo, Risso Domenico, Botta Federica, Chiarbonello Bruno, Fasoli Alberto, Malfatti Federica, Romagnoli Paola, Testa Emanuela, Ceppa Paola, Testa Roberto
Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, No. 6, 16132 Genoa, Italy.
Arch Intern Med. 2003 Jan 27;163(2):218-24. doi: 10.1001/archinte.163.2.218.
The aspartate aminotransferase-alanine aminotransferase ratio (AST/ALT ratio) has been used to noninvasively assess the severity of disease in patients with chronic liver disease (CLD). We previously demonstrated that progressive liver functional impairment is associated with an increase in the AST/ALT ratio.
To evaluate the reproducibility and transportability of the AST/ALT ratio in a large cohort of patients with different degrees of hepatitis C virus (HCV)-related CLD, to confirm the correlation between progressive impairment of liver function and increase in the AST/ALT ratio, to evaluate whether diagnostic accuracy of the ALT/AST ratio can be improved by using it with other biochemical variables, and to assess the 1-year prognostic capability of the AST/ALT ratio in patients with liver cirrhosis.
We retrospectively evaluated 252 patients with HCV-related CLD. The AST/ALT ratio was correlated with the degree of liver fibrosis in patients with chronic hepatitis and with the Child-Pugh score in patients with cirrhosis. All patients had undergone monoethylglycinexylidide (MEGX) testing to evaluate liver function. We assessed the prognostic ability of the AST/ALT ratio in a subset of 63 cirrhotic patients who were followed up for at least 1 year.
The AST/ALT ratio was more frequently 1 or higher in cirrhotic patients (P<.001). There was a significant correlation between MEGX values and the AST/ALT ratio (r(s) = -0.621, P<.001). Multivariate stepwise logistic analysis showed that AST/ALT ratio, platelet count (PLT), MEGX values, and prothrombin activity were independently associated with the presence of cirrhosis. Combined assessment of the AST/ALT ratio and/or PLT obtained 97.0% positive predictive value and 97.9% negative predictive value for the diagnosis of cirrhosis. The AST/ALT ratio had 81.3% sensitivity and 55.3% specificity in identifying cirrhotic patients who died within 1-year of follow-up.
The AST/ALT ratio is both reproducible and transportable in patients with HCV-related CLD. The AST/ALT ratio is correlated with both histologic stage and clinical evaluation. Progressive liver functional impairment is reflected by an increase in the AST/ALT ratio. Noninvasive evaluation by means of the combined AST/ALT ratio and PLT assessment misclassifies only a few cirrhotic patients. In cirrhotic patients, the AST/ALT ratio provides medium-term prognostic information that is no different from that provided by established prognostic scores.
天冬氨酸氨基转移酶与丙氨酸氨基转移酶比值(AST/ALT比值)已被用于无创评估慢性肝病(CLD)患者的疾病严重程度。我们之前证明,肝功能进行性损害与AST/ALT比值升高有关。
评估AST/ALT比值在一大群不同程度丙型肝炎病毒(HCV)相关CLD患者中的可重复性和可转移性,确认肝功能进行性损害与AST/ALT比值升高之间的相关性,评估联合其他生化变量使用ALT/AST比值是否能提高诊断准确性,以及评估AST/ALT比值对肝硬化患者的1年预后预测能力。
我们回顾性评估了252例HCV相关CLD患者。AST/ALT比值与慢性肝炎患者的肝纤维化程度以及肝硬化患者的Child-Pugh评分相关。所有患者均接受了单乙基甘氨酸二甲苯酰胺(MEGX)检测以评估肝功能。我们评估了63例至少随访1年的肝硬化患者亚组中AST/ALT比值的预后预测能力。
肝硬化患者中AST/ALT比值≥1更为常见(P<0.001)。MEGX值与AST/ALT比值之间存在显著相关性(rs=-0.621,P <0.001)。多因素逐步逻辑回归分析显示,AST/ALT比值、血小板计数(PLT)、MEGX值和凝血酶原活动度与肝硬化的存在独立相关。联合评估AST/ALT比值和/或PLT对肝硬化诊断的阳性预测值为97.0%,阴性预测值为97.9%。AST/ALT比值在识别随访1年内死亡的肝硬化患者中,敏感性为81.3%,特异性为55.3%。
AST/ALT比值在HCV相关CLD患者中具有可重复性和可转移性。AST/ALT比值与组织学分期和临床评估均相关。肝功能进行性损害表现为AST/ALT比值升高。联合AST/ALT比值和PLT评估的无创性评估仅使少数肝硬化患者误诊。在肝硬化患者中,AST/ALT比值提供的中期预后信息与既定的预后评分所提供的信息无异。